A Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of Low-dose Adjunctive alTeplase During prIMary PCI
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 May 2018
At a glance
- Drugs Alteplase (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms T-TIME
- 09 May 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated